Where Are We Now in Moderate-to-Severe Asthma?

From Comprehensive Patient Evaluations to Individualized Evidence-Based Care

In this 4-part CME SnapshotTM series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

This activity is jointly provided by Global Education Group and Integritas Communications.

 

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

Image SnapShot

credit amount 0.25

credit type CME/CE

expiration 06/08/2022

Image SnapShot

credit amount 0.25

credit type CME/CE

expiration 05/14/2022

Image SnapShot
A Case-Based Look at Managing Moderate-to-Severe Asthma

Module 3

Jonathan Corren, MD; Monica Kraft, MD
MODULE 3
Begin Activity

credit amount 0.25

credit type CME/CE

expiration 06/21/2022

Image SnapShot
MODULE 4
Begin Activity

credit amount 0.50

credit type CME/CE

expiration 07/13/2022

Resource

Where are We Now In Moderate-to-Severe Asthma?

From Comprehensive Patient Evaluations to Individualized Evidence-based Care